Understanding MN1: A Potential Drug Target for Meningioma (G4330)

Target Name: MN1

NCBI ID: G4330

Content of Review Report on MN1 Target / Biomarker

MN1

Understanding MN1: A Potential Drug Target for Meningioma

Meningioma, also known as meningioma, is a type of brain cancer that arises from glial cells, which support and protect nerve cells. Despite being a relatively common type of cancer, meningioma is often treated with great difficulty due to its tendency to recur and the high mortality rate associated with the disease.

One potential drug target for meningioma is MN1, a protein that is expressed in the brains of people with meningioma. MN1 has been shown to play a role in the development and progression of the disease, and may be a useful target for new treatments.

Research on MN1 has led to the identification of several potential drug targets, including the tyrosine kinase FAK and the nuclear factor kappa B (NF-kappa-B). These targets are thought to be involved in the regulation of cell growth, survival, and angiogenesis, which are all key factors in the development of meningioma.

One of the key challenges in studying MN1 is its complex expression pattern in the brain. While MN1 is often expressed in meningioma tissue, it is not always present at high levels, and its levels can vary depending on the stage and location of the disease. This makes it difficult to use MN1 as a reliable biomarker for the disease.

However, researchers have been able to use MN1 as a potential drug target by using techniques such as RNA interference and gene editing to knock down or activate the expression of MN1. These studies have led to the identification of several potential targets for MN1, including the tyrosine kinase FAK, the nuclear factor kappa B (NF-kappa-B), and the serine/threonine kinasePyk5.

The tyrosine kinase FAK is a protein that is involved in the regulation of cell growth and survival. It has been shown to be involved in the development and progression of meningioma, and may be a potential target for new treatments.

The nuclear factor kappa B (NF-kappa-B) is a protein that is involved in the regulation of inflammation and cell survival. It has been shown to be involved in the development and progression of meningioma, and may be a potential target for new treatments.

The serine/threonine kinasePyk5 is a protein that is involved in the regulation of cell growth and survival. It has been shown to be involved in the development and progression of meningioma, and may be a potential target for new treatments.

While the study of MN1 as a potential drug target is still in its early stages, it holds great promise as a new treatment option for meningioma. Further research is needed to fully understand the role of MN1 in the development and progression of the disease, and to identify effective strategies for using it as a drug target.

Protein Name: MN1 Proto-oncogene, Transcriptional Regulator

Functions: Transcriptional activator which specifically regulates expression of TBX22 in the posterior region of the developing palate. Required during later stages of palate development for growth and medial fusion of the palatal shelves. Promotes maturation and normal function of calvarial osteoblasts, including expression of the osteoclastogenic cytokine TNFSF11/RANKL. Necessary for normal development of the membranous bones of the skull (By similarity). May play a role in tumor suppression (Probable)

The "MN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets